Ayvens : The comeback of an upward trend can be anticipated
Entry price | Target | Stop-loss | Potential |
---|
€10.98 |
€13.1 |
€9.9 |
+19.31% |
---|
The technical chart pattern of ALD shares shows signs of a medium term reversal, which speaks in favor of opening new long positions.
Strengths● The share is getting closer to its long-term support in weekly data, at EUR 9.94, which offers good timing for buyers.
● Share prices are approaching a strong support area in daily data, which offers good timing for investors.
● Considering the small differences between the analysts' various estimates, the group's business visibility is good.
● Its low valuation, with P/E ratio at 7.89 and 7.64 for the ongoing fiscal year and 2019 respectively, makes the stock pretty attractive with regard to earnings multiples.
● This company will be of major interest to investors in search of a high dividend stock.
● The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses● The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
● Below the resistance at 13.6 EUR, the stock shows a negative configuration when looking looking at the weekly chart.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.